Figure 4.

Data from the ATTRACT (Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy) study showing the superiority of infliximab plus methotrexate (MTX) over methotrexate alone, as determined by the median change in the modified Sharp score. Data from [12].

Yocum Arthritis Res Ther 2004 6(Suppl 2):S24-S30   doi:10.1186/ar997